Distinct genetic and epigenetic signatures of colorectal cancers according to ethnic origin

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 1, 2012, Pages 202-211

  Nieminen, Taina T ^a   Shoman, Soheir ^b   Eissa, Saad ^b   Peltomäki, Päivi ^a   Abdel Rahman, Wael M ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c UNIVERSITY OF SHARJAH   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA; FLICE INHIBITORY PROTEIN; GLUTATHIONE TRANSFERASE P1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; WNT PROTEIN;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER GENETICS; CANCER STAGING; COLON CARCINOGENESIS; COLORECTAL CANCER; COMPARATIVE STUDY; DISEASE ASSOCIATION; EGYPT; EPIGENETICS; ETHNIC GROUP; FAMILIAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METHYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; BETA CATENIN; COLORECTAL NEOPLASMS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; EGYPT; EPIGENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84855502899     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0662     Document Type: Article

References (42)

1. Dajani YF, Zayid I, Malatjalian DA, Kamal MF. Colorectal cancer in Jordan and Nova Scotia: a comparative epidemiologic and histopathologic study. Cancer 1980;46:420-8.
2. Isbister WH. Colorectal cancer below age 40 in the Kingdom of Saudi Arabia. Aust N Z J Surg 1992;62:468-72.
3. Soliman AS, Bondy ML, Levin B, Hamza MR, Ismail K, Ismail S, et al. Colorectal cancer in Egyptian patients under 40 years of age. Int J Cancer 1997;71:26-30. (Pubitemid 27158405)
4. Abou-Zeid AA, Khafagy W, Marzouk DM, Alaa A, Mostafa I, Ela MA. Colorectal cancer in Egypt. Dis Colon Rectum 2002;45:1255-60.
5. Soliman AS, Bondy ML, Levin B, El-Badawy S, Khaled H, Hablas A, et al. Familial aggregation of colorectal cancer in Egypt. Int J Cancer 1998;77:811-6. (Pubitemid 28378124)
6. da Costa LT, He TC, Yu J, Sparks AB, Morin PJ, Polyak K, et al. CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. Oncogene 1999;18:5010-4. (Pubitemid 29425309)
7. Abdel-Rahman WM, Lohi H, Knuutila S, Peltomaki P. Restoring mismatch repair does not stop the formation of reciprocal translocations in the colon cancer cell line HCA7 but further destabilizes chromosome number. Oncogene 2005;24:706-13. (Pubitemid 40188575)
8. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 2004;127:1578-88. (Pubitemid 39457781)
9. Abdel-Rahman WM. Genomic instability and carcinogenesis: an update. Curr Genomics 2008;9:535-41.
10. Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, Peltomaki P. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res 2008;68:4597-605.
11. Chan AO, Soliman AS, Zhang Q, Rashid A, Bedeir A, Houlihan PS, et al. Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. Clin Cancer Res 2005;11:8281-7. (Pubitemid 41746938)
12. Renkonen E, Zhang YG, Lohi H, Salovaara R, Abdel-Rahman WM, Nilbert M, et al. Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. J Clin Oncol 2003;21:3629-37. (Pubitemid 46594056)
13. Abdel-Rahman WM, Ollikainen M, Kariola R, Jarvinen HJ, Mecklin JP, Nystrom-Lahti M, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 2005;24:1542-51. (Pubitemid 40396084)
14. Fidalgo PO, Cravo ML, Nobre-Leitao C. Re: A National Cancer Institute Workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda Guidelines. J Natl Cancer Inst 1998;90:939-40.
15. Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, Jarvinen H, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001;61:4545-9. (Pubitemid 32685787)
16. Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, et al. Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay. Ann Surg Oncol 2010;17:3370-8.
17. MRC Holland. [cited June 20, 2011]. Available from: http://www.mrc- holland.com.
18. Richard Lowry, PhD, Vassar College. [cited July 12, 2011]. Available from: http://faculty.vassar.edu/lowry/VassarStats.html.
19. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6. (Pubitemid 29258894)
20. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8. (Pubitemid 38256271)
21. Yao J, Eu KW, Seow-Choen F, Vijayan V, Cheah PY. Microsatellite instability and aneuploidy rate in young colorectal-cancer patients do not differ significantly from those in older patients. Int J Cancer 1999;80:667-70. (Pubitemid 29066275)
22. Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S, Bayoumy S, et al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer 2001;85:1037-46. (Pubitemid 33016007)
23. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-75. (Pubitemid 44572384)
24. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95. (Pubitemid 32204552)
25. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer 2011;128:1080-94.
26. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9. (Pubitemid 32695003)
27. Cheng YW, Shawber C, Notterman D, Paty P, Barany F. Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay. Genome Res 2006;16:282-9. (Pubitemid 43200277)
28. Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 2004;10:3441-54.
29. Marsit CJ, Kim DH, Liu M, Hinds PW, Wiencke JK, Nelson HH, et al. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. Int J Cancer 2005;114:219-23. (Pubitemid 40194289)
30. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24. (Pubitemid 32695035)
31. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003;23:5293-300. (Pubitemid 36950884)
32. Pufulete M, Al-Ghnaniem R, Khushal A, Appleby P, Harris N, Gout S, et al. Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. Gut 2005;54:648-53. (Pubitemid 40559249)
33. Ulrich CM, Potter JD. Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 2006;15:189-93. (Pubitemid 43342163)
34. Lo AC, Soliman AS, Khaled HM, Aboelyazid A, Greenson JK. Lifestyle, occupational, and reproductive factors and risk of colorectal cancer. Dis Colon Rectum 2010;53:830-7.
35. Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006;27:112-6. (Pubitemid 43025250)
36. Belinsky SA, Klinge DM, Liechty KC, March TH, Kang T, Gilliland FD, et al. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. Carcinogenesis 2004;25:1063-7. (Pubitemid 38886088)
37. Vuillemenot BR, Pulling LC, Palmisano WA, Hutt JA, Belinsky SA. Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. Carcinogenesis 2004;25:623-9. (Pubitemid 38499951)
38. Abdel-Rahman WM, Kalinina J, Shoman S, Eissa S, Ollikainen M, Elomaa O, et al. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin. Hum Mutat 2008;29:390-7. (Pubitemid 351364941)
39. Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 2010;29:1653-62.
40. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. (Pubitemid 26358996)
41. van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005;11:496-502. (Pubitemid 41653290)
42. Issa JP. Colon cancer: it's CIN or CIMP. Clin Cancer Res 2008;14:5939-40.